Vosoritide dosage in published studies and labels

These are the doses used for Vosoritide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Vosoritide has an FDA-approved human dosage as Voxzogo, to increase linear growth in children with achondroplasia whose growth plates are still open, under accelerated approval. It is given once daily by subcutaneous injection at a dose set by body weight band, from 0.096 mg at 3 kg to 0.8 mg at 90 kg or more, after adequate food and about 240–300 mL of fluid.

FDA Approved

Dosage evidence summary for Vosoritide
Human dosing established	Yes
Route	Subcutaneous
Frequency	Once daily, at about the same time each day
Duration studied	Until the growth plates close
Titration	No escalation: the dose follows the child's actual body weight band and is re-checked every 3 to 6 months.
Half-life	Mean half-life of 21.0 to 27.9 minutes (Voxzogo label)
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Vosoritide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Voxzogo, achondroplasiaFDA-approved label · FDA prescribing information	Children with achondroplasia and open epiphyses	By weight band: 0.096 mg at 3 kg, 0.12 mg at 4 kg, 0.16 mg at 5 kg, 0.2 mg at 6–7 kg, 0.24 mg at 8–11 kg, 0.28 mg at 12–16 kg, 0.32 mg at 17–21 kg, 0.4 mg at 22–32 kg, 0.5 mg at 33–43 kg, 0.6 mg at 44–59 kg, 0.7 mg at 60–89 kg, 0.8 mg at 90 kg or more	Subcutaneous, rotating sites	Once daily	Stopped once the growth plates close	Annualised growth velocity: in the label's 52-week placebo-controlled study (121 children aged 5 to 14 given 15 mcg/kg daily), the treatment difference was 1.57 cm/year	VOXZOGO (vosoritide) for injection — FDA prescribing information, DailyMed

Where sources disagree

Voxzogo's approval is accelerated, based on annualised growth velocity; continued approval may depend on confirmatory trials. The label's phase 3 study used 15 mcg/kg once daily, and the label's weight-band table gives fixed doses in milligrams.
The label warns of transient drops in blood pressure, which is why each dose follows adequate food and about 240–300 mL of fluid in the hour before. Children with significant heart or vascular disease and those on blood pressure medicines were excluded from the trials.
Voxzogo comes as kits of single-dose powder vials (0.4, 0.56 and 1.2 mg), each with a prefilled syringe of sterile water: 0.5 mL for the 0.4 mg vial and 0.7 mL for the 0.56 mg vial give 0.8 mg/mL, and 0.6 mL for the 1.2 mg vial gives 2 mg/mL. One dose is taken per vial and the rest discarded. Vosoritide is a C-type natriuretic peptide analogue.